FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

por Tillman, Erik J., Rolph, Tim
Publicado 2020

Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats

por Tillman, Erik J., Brock, William J., Rolph, Tim
Publicado 2022

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients

por Kaufman, Allegra, Abuqayyas, Lubna, Denney, William S., Tillman, Erik J., Rolph, Tim
Publicado 2020

Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain

por Lintner, Nathanael G., McClure, Kim F., Petersen, Donna, Londregan, Allyn T., Piotrowski, David W., Wei, Liuqing, Xiao, Jun, Bolt, Michael, Loria, Paula M., Maguire, Bruce, Geoghegan, Kieran F., Huang, Austin, Rolph, Tim, Liras, Spiros, Doudna, Jennifer A., Dullea, Robert G., Cate, Jamie H. D.
Publicado 2017

Correction: Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain

por Lintner, Nathanael G., McClure, Kim F., Petersen, Donna, Londregan, Allyn T., Piotrowski, David W., Wei, Liuqing, Xiao, Jun, Bolt, Michael, Loria, Paula M., Maguire, Bruce, Geoghegan, Kieran F., Huang, Austin, Rolph, Tim, Liras, Spiros, Doudna, Jennifer A., Dullea, Robert G., Cate, Jamie H. D.
Publicado 2018